{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:08:51Z","timestamp":1786993731517,"version":"build-2736575974"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["52912555"],"award-info":[{"award-number":["52912555"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.lungcan.2025.108710","type":"journal-article","created":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T05:49:26Z","timestamp":1754891366000},"page":"108710","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Dacomitinib in the treatment of EGFR-mutated non-small cell lung cancer with brain metastases: an open-label, multicenter, phase II study"],"prefix":"10.1016","volume":"207","author":[{"given":"Yongfeng","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueyin","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianya","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuya","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8833-7262","authenticated-orcid":false,"given":"Shun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.lungcan.2025.108710_b0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"9","key":"10.1016\/j.lungcan.2025.108710_b0010","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/s41571-023-00798-3","article-title":"The global burden of lung cancer: current status and future trends","volume":"20","author":"Leiter","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"13","key":"10.1016\/j.lungcan.2025.108710_b0015","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25136961","article-title":"A review of the molecular determinants of therapeutic response in non-small cell lung cancer brain metastases","volume":"25","author":"Boldig","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108710_b0020","doi-asserted-by":"crossref","DOI":"10.1080\/20450907.2024.2395804","article-title":"Development of brain metastases in non-small-cell lung cancer: high-risk features","volume":"13","author":"Winslow","year":"2024","journal-title":"CNS Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108710_b0025","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.lungcan.2015.01.020","article-title":"Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers","volume":"88","author":"Rangachari","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2025.108710_b0030","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ejca.2020.03.006","article-title":"Systemic treatment of brain metastases in non-small cell lung cancer","volume":"132","author":"Page","year":"2020","journal-title":"Eur. J. Cancer"},{"issue":"12","key":"10.1016\/j.lungcan.2025.108710_b0035","first-page":"6160","article-title":"Surgical resection of brain metastases prolongs overall survival in non-small-cell lung cancer","volume":"11","author":"Yen","year":"2021","journal-title":"Am. J. Cancer Res."},{"issue":"3","key":"10.1016\/j.lungcan.2025.108710_b0040","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1007\/s11547-023-01602-z","article-title":"The role of brain radiotherapy for EGFR- and ALK-positive non-small-cell lung cancer with brain metastases: a review","volume":"128","author":"Nardone","year":"2023","journal-title":"Radiol. Med."},{"key":"10.1016\/j.lungcan.2025.108710_b0045","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.lungcan.2018.12.025","article-title":"Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer","volume":"129","author":"Crino","year":"2019","journal-title":"Lung Cancer"},{"issue":"14","key":"10.1016\/j.lungcan.2025.108710_b0050","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1200\/JCO.19.03136","article-title":"Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer","volume":"38","author":"Gadgeel","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2025.108710_b0055","article-title":"Adjuvant EGFR-TKI therapy in resected EGFR-mutation positive non-small cell lung cancer: a real-world study","volume":"13","author":"Liu","year":"2023","journal-title":"Front. Oncol."},{"issue":"11","key":"10.1016\/j.lungcan.2025.108710_b0060","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/j.annonc.2020.08.2100","article-title":"Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis","volume":"31","author":"Papadimitrakopoulou","year":"2020","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108710_b0065","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.lungcan.2025.108710_b0070","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s40265-019-01115-y","article-title":"Dacomitinib in the management of advanced non-small-cell lung cancer","volume":"79","author":"Lau","year":"2019","journal-title":"Drugs"},{"issue":"11","key":"10.1016\/j.lungcan.2025.108710_b0075","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/S1470-2045(17)30608-3","article-title":"Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial","volume":"18","author":"Wu","year":"2017","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2025.108710_b0080","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1124\/dmd.118.084210","article-title":"Brain distribution of a panel of epidermal growth factor receptor inhibitors using cassette dosing in wild-type and Abcb1\/Abcg2-deficient mice","volume":"47","author":"Kim","year":"2019","journal-title":"Drug Metab. Dispos."},{"issue":"4","key":"10.1016\/j.lungcan.2025.108710_b0085","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1002\/cam4.4495","article-title":"A real-world study of dacomitinib in later-line settings for advanced non-small cell lung cancer patients harboring EGFR mutations","volume":"11","author":"Li","year":"2022","journal-title":"Cancer Med."},{"issue":"24","key":"10.1016\/j.lungcan.2025.108710_b0090","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1111\/1759-7714.14222","article-title":"Efficacy of dacomitinib in patients with EGFR-mutated NSCLC and brain metastases","volume":"12","author":"Zhang","year":"2021","journal-title":"Thorac Cancer."},{"key":"10.1016\/j.lungcan.2025.108710_b0095","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.lungcan.2020.12.008","article-title":"Dacomitinib induces objective responses in metastatic brain lesions of patients with EGFR-mutant non-small-cell lung cancer: a brief report","volume":"152","author":"Peng","year":"2021","journal-title":"Lung Cancer"},{"issue":"6","key":"10.1016\/j.lungcan.2025.108710_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.102068","article-title":"Dacomitinib in EGFR-mutant non-small-cell lung cancer with brain metastasis: a single-arm, phase II study","volume":"8","author":"Jung","year":"2023","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.lungcan.2025.108710_b0105","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41568-019-0205-x","article-title":"The blood-brain barrier and blood-tumour barrier in brain tumours and metastases","volume":"20","author":"Arvanitis","year":"2020","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"10.1016\/j.lungcan.2025.108710_b0110","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000014110","article-title":"Effect of pemetrexed on brain metastases from nonsmall cell lung cancer with wild-type and unknown EGFR status","volume":"98","author":"Yu","year":"2019","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.lungcan.2025.108710_b0115","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1158\/1078-0432.CCR-19-1871","article-title":"Preclinical comparison of the blood-brain barrier permeability of osimertinib with other EGFR TKIs","volume":"27","author":"Colclough","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.lungcan.2025.108710_b0120","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1016\/j.jtho.2021.07.026","article-title":"A phase II study of osimertinib for radiotherapy-naive central nervous system metastasis from NSCLC: results for the T790M cohort of the OCEAN Study (LOGIK1603\/WJOG9116L)","volume":"16","author":"Yamaguchi","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108710_b0125","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1186\/s13014-021-01955-7","article-title":"Therapeutic effect of osimertinib plus cranial radiotherapy compared to osimertinib alone in NSCLC patients with EGFR-activating mutations and brain metastases: a retrospective study","volume":"16","author":"Zhai","year":"2021","journal-title":"Radiat. Oncol."},{"key":"10.1016\/j.lungcan.2025.108710_b0130","first-page":"6101","article-title":"Anlotinib combined with cranial radiotherapy for non-small cell lung cancer patients with brain metastasis: a retrospectively","volume":"13","author":"He","year":"2021","journal-title":"Control Study. Cancer Manag Res."},{"key":"10.1016\/j.lungcan.2025.108710_b0135","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1169333","article-title":"Anlotinib combined with whole-brain radiotherapy in non-small cell lung cancer with multiple brain metastases that progressed or developed after at least one lines of prior treatment","volume":"13","author":"Kong","year":"2023","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2025.108710_b0140","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.cllc.2017.10.003","article-title":"Effect of brain metastasis on patient-reported outcomes in advanced NSCLC treated in real-world community oncology settings","volume":"19","author":"Walker","year":"2018","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.lungcan.2025.108710_b0145","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3332\/ecancer.2017.779","article-title":"Prognostic value of a patient-reported functional score versus physician-reported Karnofsky performance status score in brain metastases","volume":"11","author":"Agarwal","year":"2017","journal-title":"Ecancermedicalscience"},{"issue":"9","key":"10.1016\/j.lungcan.2025.108710_b0150","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1158\/1078-0432.CCR-16-0966","article-title":"Impact of TP53 mutations on outcome in EGFR-mutated patients treated with first-line tyrosine kinase inhibitors","volume":"23","author":"Canale","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2025.108710_b0155","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.lungcan.2017.06.014","article-title":"Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC)","volume":"111","author":"Labb\u00e9","year":"2017","journal-title":"Lung Cancer"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225006026?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225006026?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T14:41:14Z","timestamp":1757083274000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500225006026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":31,"alternative-id":["S0169500225006026"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108710","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dacomitinib in the treatment of EGFR-mutated non-small cell lung cancer with brain metastases: an open-label, multicenter, phase II study","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108710","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108710"}}